CTOs on the Move

Dthera

www.dthera.com

 
Dthera™ Sciences (OTCQB:DTHR) is the leading digital therapeutic company focusing on the elderly. The San Diego-based, publicly traded company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. It has two core products: ReminX™, a commercially available consumer health product for individuals suffering from social isolation and dementia; and DTHR-ALZ, and a development-stage product that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer`s disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dthera.com
  • 7310 Miramar Road Suite 350
    San Diego, CA USA 92126
  • Phone: 858.215.6360

Executives

Name Title Contact Details

Similar Companies

Swede-O

Swede-O, Inc. is a North Branch, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nu Life Long Island

Nu Life Long Island is a West Hempstead, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Optident

Optident is a Springfield, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TOPSPINS

TOPSPINS is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ability to offer peace of mind to patients while benefitting physicians, who may wish to reduce safety concerns, side effects and adverse events for their patients.